Victoria W Willard1, Ibrahim Qaddoumi1, Si Chen1, Hui Zhang1, Rachel Brennan1, Carlos Rodriguez-Galindo1, Matthew W Wilson1, Sean Phipps2. 1. Victoria W. Willard, Ibrahim Qaddoumi, Si Chen, Hui Zhang, Rachel Brennan, and Sean Phipps, St Jude Children's Research Hospital; Matthew W. Wilson, University of Tennessee, Memphis, TN; and Carlos Rodriguez-Galindo, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA. 2. Victoria W. Willard, Ibrahim Qaddoumi, Si Chen, Hui Zhang, Rachel Brennan, and Sean Phipps, St Jude Children's Research Hospital; Matthew W. Wilson, University of Tennessee, Memphis, TN; and Carlos Rodriguez-Galindo, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA. sean.phipps@stjude.org.
Abstract
PURPOSE: To determine the developmental trajectory of early cognitive and adaptive skills in young children with retinoblastoma from diagnosis to 5 years of age. PATIENTS AND METHODS: Ninety-four patients with retinoblastoma treated according to an institutional protocol underwent serial assessments of cognitive and adaptive functioning at age 6 months and 1, 2, 3, and 5 years. Data were analyzed by treatment strata, with patients with 13q deletion analyzed separately. RESULTS: At baseline, across all patients (except those with 13q deletion), developmental functioning was comparable with the normative mean, with mean scores for all strata within the average range. However, at age 5 years, developmental functioning was in the low average range and significantly below normative means. The trajectories of developmental functioning demonstrated significant decline over time, although this varied by treatment group/strata. Patients treated with enucleation only evidenced the greatest decline in cognitive functioning; significant change was not observed in patients treated with other modalities. Notable declines in parent-reported communication skills were observed in the majority of patients. Patients with 13q deletion evidenced delayed cognitive functioning at baseline, but minimal declines were observed through age 3 years. However, significant decreases in adaptive functioning were demonstrated over time for the 13q deletion subset. CONCLUSION: The declines in functioning observed in this study were unexpected, as was the poorer performance of the enucleation-only group. This highlights the necessity of continuing to assess cognitive functioning in patients with retinoblastoma as they age. Additional research is necessary to determine the long-term trajectory of cognitive development in this population.
PURPOSE: To determine the developmental trajectory of early cognitive and adaptive skills in young children with retinoblastoma from diagnosis to 5 years of age. PATIENTS AND METHODS: Ninety-four patients with retinoblastoma treated according to an institutional protocol underwent serial assessments of cognitive and adaptive functioning at age 6 months and 1, 2, 3, and 5 years. Data were analyzed by treatment strata, with patients with 13q deletion analyzed separately. RESULTS: At baseline, across all patients (except those with 13q deletion), developmental functioning was comparable with the normative mean, with mean scores for all strata within the average range. However, at age 5 years, developmental functioning was in the low average range and significantly below normative means. The trajectories of developmental functioning demonstrated significant decline over time, although this varied by treatment group/strata. Patients treated with enucleation only evidenced the greatest decline in cognitive functioning; significant change was not observed in patients treated with other modalities. Notable declines in parent-reported communication skills were observed in the majority of patients. Patients with 13q deletion evidenced delayed cognitive functioning at baseline, but minimal declines were observed through age 3 years. However, significant decreases in adaptive functioning were demonstrated over time for the 13q deletion subset. CONCLUSION: The declines in functioning observed in this study were unexpected, as was the poorer performance of the enucleation-only group. This highlights the necessity of continuing to assess cognitive functioning in patients with retinoblastoma as they age. Additional research is necessary to determine the long-term trajectory of cognitive development in this population.
Authors: Jessica Sparrow; Rachel Brennan; Shenghua Mao; Kirsten K Ness; Carlos Rodriguez-Galindo; Matthew Wilson; Ibrahim Qaddoumi Journal: J Pediatr Rehabil Med Date: 2016-05-31
Authors: Smita C Banerjee; Elaine Pottenger; Mary Petriccione; Joanne F Chou; Jennifer S Ford; Charles A Sklar; Leslie L Robison; Ruth A Kleinerman; Kevin C Oeffinger; Jasmine H Francis; David H Abramson; Ira J Dunkel; Danielle Novetsky Friedman Journal: Palliat Support Care Date: 2020-06
Authors: Victoria W Willard; Ibrahim Qaddoumi; Hui Zhang; Lu Huang; Kathryn M Russell; Rachel Brennan; Matthew W Wilson; Carlos Rodriguez-Galindo; Sean Phipps Journal: Pediatr Blood Cancer Date: 2016-11-03 Impact factor: 3.167
Authors: Helen Dimaras; Timothy W Corson; David Cobrinik; Abby White; Junyang Zhao; Francis L Munier; David H Abramson; Carol L Shields; Guillermo L Chantada; Festus Njuguna; Brenda L Gallie Journal: Nat Rev Dis Primers Date: 2015-08-27 Impact factor: 52.329
Authors: Victoria W Willard; Ibrahim Qaddoumi; Haitao Pan; Chia-Wei Hsu; Rachel C Brennan; Matthew W Wilson; Carlos Rodriguez-Galindo; Kristin Goode; Kendra Parris; Sean Phipps Journal: J Clin Oncol Date: 2021-04-23 Impact factor: 50.717